466-77-3 Usage
Description
Erythraline, also known as (+)-erythraline, is a natural compound derived from Erythrina plant species. It possesses curariform or paralytic activity, which makes it a compound of interest for various applications.
Uses
Used in Pharmaceutical Industry:
Erythraline is used as a compound with curariform/paralytic activity for its potential applications in the development of pharmaceuticals targeting muscle relaxation or paralysis. Its paralytic properties could be utilized in the creation of medications for specific conditions that require muscle control or as an adjunct in surgical procedures.
Used in Research and Development:
In the field of research and development, erythraline serves as a valuable compound for studying the effects of curariform/paralytic agents on the human body. This can lead to a better understanding of muscle function and the development of new therapeutic approaches for related conditions.
Used in Toxicology Studies:
Erythraline's paralytic activity also makes it a useful tool in toxicology studies, where it can be employed to investigate the mechanisms of action of similar compounds and their potential risks or benefits to human health.
Check Digit Verification of cas no
The CAS Registry Mumber 466-77-3 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 4,6 and 6 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 466-77:
(5*4)+(4*6)+(3*6)+(2*7)+(1*7)=83
83 % 10 = 3
So 466-77-3 is a valid CAS Registry Number.
InChI:InChI=1/C18H19NO3/c1-20-14-3-2-13-5-7-19-6-4-12-8-16-17(22-11-21-16)9-15(12)18(13,19)10-14/h2-3,5,8-9,14H,4,6-7,10-11H2,1H3/t14-,18-/m0/s1
466-77-3Relevant articles and documents
Development of a Divergent Synthetic Route to the Erythrina Alkaloids: Asymmetric Syntheses of 8-Oxo-erythrinine, Crystamidine, 8-Oxo-erythraline, and Erythraline
Umihara, Hirotatsu,Yoshino, Tomomi,Shimokawa, Jun,Kitamura, Masato,Fukuyama, Tohru
, p. 6915 - 6918 (2016/06/14)
A general synthetic methodology toward the erythrina alkaloids has been developed. Inspired by a proposed biosynthetic mechanism, the medium-sized chiral biaryl lactam was asymmetrically transformed into the common core A-D rings by a stereospecific singlet oxygen oxidation of the phenol moiety, followed by a transannular aza-Michael reaction to the dienone functionality. The late-stage manipulation of the oxidation and oxygenation states of the functional groups on the peripheral moieties enabled the flexible syntheses of the erythrina alkaloids. Then there were four: The fixed atropisomeric stereochemistry of a medium-sized biaryl intermediate was fully transferred to the central point chirality of a helical intermediate as a result of singlet oxygen oxidation and transannulation. This finding enabled the asymmetric synthesis of a common intermediate, which is amenable to a variety of oxidation-reduction transformations, thus giving rise to the first asymmetric syntheses of four erythrina alkaloids.
SYNTHESES OF ERYTHRINA AND RELATED ALKALOIDS (6) TOTAL SYNTHESIS OF ERYSOTRINE AND ERYTHRALINE
Sano, Takehiro,Toda, Jun,Tsuda, Yoshisuke
, p. 229 - 232 (2007/10/02)
An efficiently stereocontrolled synthesis of the erythrina alkaloids, erysotrine and erythraline was described.
